AGA Medical Corp. manufactures medical devices used to treat structural heart defects and abnormal blood vessels. Its AMPLATZER products help improve patient outcomes, reduce length of hospital stay, and accelerate patient recovery times. The company was founded by Kurt Amplatz and Franck L. Gougeon on July 12, 1995 and is headquartered in Plymouth, MN.

Part of Abbott Laboratories, St. Jude Medical, Cardiology Division, Inc. is a company headquartered in St. Paul, MN. The firm develops and commercializes minimally invasive cardiovascular and neurovascular medical devices. It was founded by Paul R. Buckman. Lisa D. Earnhardt is currently the CEO of the company.

Regents of The University of Michigan provides administers bonds on behalf of the University. The company is headquartered in Ann Arbor, MI.

GlycoMimetics, Inc., a biopharmaceutical company, engages in the design and development of small molecule therapeutics to mimic the functions of bioactive carbohydrates. Its products include GMI-1070, a synthetic glycomimetic molecule designed to inhibit selectin types, such as E, P, and L-selectin; and GMI-1051, a small molecular weight compound for the treatment or prevention of infections caused by pseudomonas aeruginosa. The company was founded in 2003 and is based in Gaithersburg, Maryland.

Manufactures healthcare equipment

Q3 Medical Devices Limited is an Irish based holding company with multiple operations in Germany. The holding and its companies are focused on the development, manufacturing, and distribution of minimally invasive devices for the treatment of patients with cardiology, peripheral vascular and non-vascular diseases. Q3 Medical Devices Limited was formed by a global group of entrepreneurs, manufactures, distributors, industry doctors, and investors focused on the development and acquisition of medical device businesses with annual revenues between 1 -10 Million. The acquisitions are targeted in areas that expand the groups manufacturing base and capabilities, growth of its distribution channels, and accelerating its products offering focused on the minimally invasive treatment of patients with cardiology, peripheral vascular and non-vascular diseases.

Blaze Bioscience is a Seattle-based, privately-held biotechnology company dedicated to developing products that assist surgeons in their quest to improve the lives of cancer patients. Tumor Paint provides real-time, high-resolution intraoperative visualization of cancer cells, enabling better detection and more complete and precise surgical resection of cancer. The first Tumor Paint product candidate, which is a combination of a targeting peptide and a fluorescent beacon, is under development for multiple solid tumors. Blaze Bioscience was founded in 2010.

Medina Medical, Inc. operates as a neurovascular company. The firm provides minimally-invasive devices for the treatment of brain aneurysms and stroke. The company was founded by Maria Aboytes and Kimberly Vogel in 2010 and is headquartered in Menlo Park, CA.

Charlesson is an Oklahoma-based pharmaceutical company located in the Presbyterian Health Foundation's Research Park. Charlesson is actively engaged in the development of therapeutics for treating debilitating ophthalmic diseases. Our product pipeline includes pharmaceutical treatments for Age-Related Macular Degeneration, Diabetic Retinopathy, Ocular Inflammation, Angiogenesis, and systemic diabetes.

Cornell provides education about the earth and atmospheric sciences. They offer summer and winter sessions. Their students contact them through phone and email services.

PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of innovative anti-cancer drugs based on lipid kinase (PI3K) and mTOR inhibition. PIQUR’s pipeline originates from one of the most promising research areas in oncology. Both PI3K and mTOR are clinically validated drug targets in oncology. PIQUR has a secured patent scope protecting many chemical compounds. PIQUR Therapeutics AG develops breakthrough targeted oncology and dermatology medicines for the treatment of cancers and genetic diseases. The company lead compound bimiralisib focuses on the dual inhibition of the PI3K/mTOR pathway. Both PI3K and mTOR are clinically validated drug targets in oncology and dermato-oncology. PIQUR Therapeutics was founded in 2011 and is based in Basel, Switzerland.

Fatigue Science Laboratory is a Community and Lifestyle.

Shinko MechaTrotech Co., Ltd. manufactures and distributes passbook entry and receipt printer machines. The company was founded in June 1937 and is headquartered in Tokyo, Japan.

CeramOptec GmbH is a company headquartered in Bonn, Germany. The firm manufactures optical fiber and lasers. It was founded in 1988. Roland Dreschau and Damian Plange are the current co-CEOs of the firm.\nThe company says this about itself: CeramOptec® in cooperation with Ceram Optec SIA offers customised solutions in fiber optic technology, from individual fibers to ready-to-use cable assemblies. With over 30 years’ experience in the development and production of optical fibers and everything that goes with it, we are a trusted partner for industry and research. We develop our precision-made solutions in-house, from preform manufacturing to finished cables and bundles, as this allows us to provide you with effective, expert support and meet your individual requirements efficiently. We offer a one-stop solution for all your fiber optics needs.

The Research Authority serves as the administrative and financial framework for research activities, scientific experiments and technical analyses carried out by Technion faculty, and TRDF staff. The missions of the Research & Development Division are: - Location, collection, processing and distribution of information concerning local and international research funding - Assistance in locating appropriate funding sources for Technion researchers - R&D information management services and in-campus marketing - Guidance and administrative services for Technion researchers in submitting research proposals to granting agencies and business entities - Management of contractual engagements with granting agencies and business entities - Contractual and budgetary administration of research grants and other accounts

CytRx is a biopharmaceutical research and development company specializing in oncology. The CytRx oncology pipeline is focused on the clinical development of aldoxorubicin (formerly known as INNO-206), its improved version of the widely used chemotherapeutic agent doxorubicin. CytRx has initiated an international Phase 2b clinical trial as a treatment for soft tissue sarcomas, has completed its Phase 1b/2 clinical trial primarily in the same indication, and has initiated a Phase 1b pharmacokinetics clinical trial in patients with metastatic solid tumors and a Phase 1b study of aldoxorubicin in combination with doxorubicin in patients with advanced solid tumors. The Company is initiating a Phase 3 pivotal trial under a special protocol assessment (SPA) with aldoxorubicin as a therapy for patients with soft tissue sarcomas whose tumors have progressed following treatment with chemotherapy. CytRx is expanding its pipeline of oncology candidates based on a novel linker platform technology that can be utilized with multiple chemotherapeutic agents and could allow for greater concentration of drug at tumor sites. The Company also has rights to two additional drug candidates, tamibarotene and bafetinib. The Company completed its evaluation of bafetinib in the ENABLE Phase 2 clinical trial in high-risk B-cell chronic lymphocytic leukemia (B-CLL), and plans to seek a partner for further development of bafetinib, and is evaluating further development of tamibarotene.

Candela Laser Corporation is an American laser company that develops and sells medical lasers for cosmetic use located in Wayland, Massachusetts.

Shinko Seisakusho KK engages in the manufacture of fabricated metal products. Its products include aluminum and metal cold forging parts for motor vehicle and motorcycle. The company is headquartered in Nagano, Japan.